On Oct. 6, 2005, when Nobuhito Kiyosato went to the Kanagawa Cancer Center, where he had been treated for kidney cancer since 2001, he was told there would be a major change in his treatment.
"My doctor told me the hospital could no longer administer LAK (lymphokine-activated killer) therapy" to boost his immune system against cancer that he had been receiving in addition to interferon, Kiyosato said.
The 60-year-old had been undergoing the LAK treatment — which was not covered by his public health insurance policy — since September 2001 when it was found that his cancer had spread to some bones in his head and cervical vertebra.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.